Imperial Innovations creates and invests in pioneering university technologies addressing healthcare, energy and environmental problems.
Business Model:
Revenue: $0
Employees: 1-10
Address: Exhibition Road
City: Greater London
State: england
Zip: SW7 2PG
Country: GB
TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye. The lead GI programme TOP1288 is currently in a Phase IIa proof of concept study in ulcerative colitis. A Phase I/II study with TOP1630 for dry eye syndrome will commence in the US in early 2017.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 12/2011 | Venture Round | 2 | $12.5M |
Imperial Innovations SV Health Investors Imperial Innovations SV Health Investors |
1/2014 | Venture Round | 4 | $7.4M |
Imperial Innovations Johnson &a; Johnson Development Corporation Neomed Management SV Health Investors Imperial Innovations Johnson &a; Johnson Development Corporation Neomed Management SV Health Investors |
4/2016 | Series A | 1 | - |
SV Health Investors SV Health Investors |
4/2016 | Series A | 1 | - |
SV Health Investors SV Health Investors |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|